Hilda Tsai

554 total citations
11 papers, 457 citations indexed

About

Hilda Tsai is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Hilda Tsai has authored 11 papers receiving a total of 457 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Hilda Tsai's work include Angiogenesis and VEGF in Cancer (9 papers), Cancer, Hypoxia, and Metabolism (6 papers) and Cancer Cells and Metastasis (5 papers). Hilda Tsai is often cited by papers focused on Angiogenesis and VEGF in Cancer (9 papers), Cancer, Hypoxia, and Metabolism (6 papers) and Cancer Cells and Metastasis (5 papers). Hilda Tsai collaborates with scholars based in United States. Hilda Tsai's co-authors include Ben K. Seon, Fumihiko Matsuno, Shima Uneda, Masanori Tsujie, Naoko Harada, Yuro Haruta, Tomoko Tsujie, Hirofumi Toi, Maurice Barcos and Masao Kondo and has published in prestigious journals such as Cancer Research, International Journal of Cancer and Cancer Immunology Immunotherapy.

In The Last Decade

Hilda Tsai

11 papers receiving 449 citations

Peers

Hilda Tsai

ONCOL

PRM

RNMI

Akinao Haba United States

Katherine A. Rybinski United States

Erin M. Conn United States

Bianca Sijmons Netherlands

Christopher R. McKenna United States

Yasuyoshi Sohara Japan

Yuro Haruta United States

Shoju Hiraga Japan

A Hill United Kingdom

Francesca Merchionne Italy

Akinao Haba United States

Hilda Tsai

252 ×0.8

157 ×0.9

ONCOL

122 ×0.8

72 ×1.1

PRM

40 ×0.6

RNMI

Citations per year, relative to Hilda Tsai Hilda Tsai (= 1×) peers Akinao Haba

Countries citing papers authored by Hilda Tsai

Since Specialization

Citations

This map shows the geographic impact of Hilda Tsai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hilda Tsai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hilda Tsai more than expected).

Fields of papers citing papers by Hilda Tsai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hilda Tsai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hilda Tsai. The network helps show where Hilda Tsai may publish in the future.

Co-authorship network of co-authors of Hilda Tsai

This figure shows the co-authorship network connecting the top 25 collaborators of Hilda Tsai. A scholar is included among the top collaborators of Hilda Tsai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hilda Tsai. Hilda Tsai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Seon, Ben K., Akinao Haba, Fumihiko Matsuno, et al.. (2010). Endoglin-Targeted Cancer Therapy. Current Drug Delivery. 8(1). 135–143. 110 indexed citations

Harada, Naoko, Norihiko Takahashi, Yuro Haruta, et al.. (2010). Abstract 378: Serum endoglin (CD105): Molecular heterogeneity and marked differences among different anti-endoglin monoclonal antibodies in the detection of metastasis and tumor progression. Cancer Research. 70(8_Supplement). 378–378. 1 indexed citations

Uneda, Shima, Hirofumi Toi, Tomoko Tsujie, et al.. (2009). Anti‐endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature. International Journal of Cancer. 125(6). 1446–1453. 54 indexed citations

Seon, Ben K., Yuro Haruta, Fumihiko Matsuno, et al.. (2009). Receptor-targeted anticancer therapy. Immunologic Research. 46(1-3). 189–191. 1 indexed citations

Tsujie, Masanori, Tomoko Tsujie, Hirofumi Toi, et al.. (2008). Anti‐tumor activity of an anti‐endoglin monoclonal antibody is enhanced in immunocompetent mice. International Journal of Cancer. 122(10). 2266–2273. 46 indexed citations

Tsujie, Tomoko, Masanori Tsujie, Yuro Haruta, et al.. (2007). Differential expression of endoglin (CD105) between human malignant epithelial tissues and cultured epithelial cell lines. Cancer Research. 67. 3826–3826. 1 indexed citations

Tsujie, Masanori, Shima Uneda, Hilda Tsai, & Ben K. Seon. (2006). Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: Differences in growth rate and therapeutic response between tumors growing at different sites. International Journal of Oncology. 29(5). 1087–94. 34 indexed citations

Harada, Naoko, William R. Greco, Akinao Haba, et al.. (2005). Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin. Cancer Immunology Immunotherapy. 55(2). 140–150. 28 indexed citations

She, Xinwei, Fumihiko Matsuno, Naoko Harada, Hilda Tsai, & Ben K. Seon. (2003). Synergy between anti‐endoglin (CD105) monoclonal antibodies and TGF‐β in suppression of growth of human endothelial cells. International Journal of Cancer. 108(2). 251–257. 53 indexed citations

10.

Matsuno, Fumihiko, Yuro Haruta, Masao Kondo, et al.. (1999). Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies.. PubMed. 5(2). 371–82. 121 indexed citations

11.

Yoshida, M., Rachel J. Rybak, Youngnim Choi, et al.. (1997). Development of a severe combined immunodeficiency (SCID) mouse model consisting of highly disseminated human B-cell leukemia/lymphoma, cure of the tumors by systemic administration of immunotoxin, and development/application of a clonotype-specific polymerase chain reaction-based assay.. PubMed. 57(4). 678–85. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact